Relationship between cholesterol synthesis and intestinal absorption is associated with cardiovascular risk

Atherosclerosis

Volumn 210, Issue 2, 2010, Pages 362-365

  Weingärtner, Oliver ^a   Lütjohann, Dieter ^b   Böhm, Michael ^a   Laufs, Ulrich ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Cardiovascular risk; Cholesterol; Lathosterol; Plant sterol; Statin

Indexed keywords

AZETIDINONE DERIVATIVE; BILE ACID SEQUESTRANT; CHOLESTEROL; COLESEVELAM; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHYTOSTEROL; STANOL ESTER;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; HUMAN; HYPERCHOLESTEROLEMIA; ILEUM BYPASS; INCIDENCE; INTESTINE ABSORPTION; ISCHEMIC HEART DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SECONDARY PREVENTION;

ABSORPTION; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTESTINES; LIVER; PHYTOSTEROLS; RISK; STEROLS;

EID: 77953229699     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.01.003     Document Type: Article

References (41)

1. National Cholesterol Education Program Expert Panel. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). National Heart, Lung, and Blood Institute, National Institutes of Health, Publication No 02-5215, 2002; 3143-421.
2. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
3. Miettinen T.A., Gylling H., Strandberg T., Sarna S. Baseline serum cholestanol as predictor of recurrent coronary events in subgroup of Scandinavian simvastatin survival study. Finnish 4S Investigators. BMJ 1998, 316:1127-1130.
4. Castelli W.P. Epidemiology of coronary heart disease: the Framingham study. Am J Med 1984, 76:4-12.
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
6. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
7. Calpe-Berdiel L., Escola-Gil J.C., Blanco-Vaca F. New insights into the molecular actions of plant sterols and stanols in cholesterol metabolism. Atherosclerosis 2009, 203:18-31.
8. Silbernagel G., Fauler G., Renner W., et al. The relationships of cholesterol metabolism and plasma plant sterols with the severity of coronary artery disease. J Lipid Res 2009, 50:334-341.
9. Matthan N.R., Pencina M., Larocque J.M., et al. Alterations in cholesterol absorption and synthesis characterize Framingham offspring study participants with coronary heart disease. J Lipid Res 2009, 50:1927-1935.
10. Miettinen T.A. Detection of changes in human cholesterol metabolism. Ann Clin Res 1970, 2:300-320.
11. Miettinen T.A., Tilvis R.S., Kesaniemi Y.A. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol 1990, 131:20-31.
12. Lütjohann D., Bjorkhem I., Beil U.F., von Bergmann K. Sterol absorption and sterol balance in phytosterolemia evaluated by deuterium-labeled sterols: effect of sitostanol treatment. J Lipid Res 1995, 36:1763-1773.
13. Kidambi S., Patel S.B. Sitosterolaemia: pathophysiology, clinical presentation and laboratory diagnosis. J Clin Pathol 2008, 61:588-594.
14. Weingärtner O., Lütjohann D., Ji S., et al. Vascular effects of diet supplementation with plant sterols. J Am Coll Cardiol 2008, 51:1553-1561.
15. Weingärtner O., Böhm M., Laufs U. Controversial role of plant sterol esters in the management of hypercholesterolaemia. Eur Heart J 2009, 30:404-409.
16. Patel M.D., Thompson P.D. Phytosterols and vascular disease. Atherosclerosis 2006, 186:12-19.
17. Miettinen T.A., Gylling H. Effect of statins on noncholesterol sterol levels: implications for use of plant stanols and sterols. Am J Cardiol 2005, 96:40D-46D.
18. Miettinen T.A., Strandberg T.E., Gylling H. Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol. Arterioscler Thromb Vasc Biol 2000, 20:1340-1346.
19. Buchwald H., Varco R.L., Matts J.P., et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990, 323:946-955.
20. Dujovne C.A., Ettinger M.P., McNeer J.F., et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol 2002, 90:1092-1097.
21. Salen G., Starc T., Sisk C.M., Patel S.B. Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis. Gastroenterology 2006, 130:1853-1857.
22. Weststrate J.A., Meijer G.W. Plant sterol-enriched margarines and reduction of plasma total- and LDL-cholesterol concentrations in normocholesterolaemic and mildly hypercholesterolaemic subjects. Eur J Clin Nutr 1998, 52:334-343.
23. Miettinen T.A., Puska P., Gylling H., Vanhanen H., Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995, 333:1308-1312.
24. Plat J., Mensink R.P. Plant stanol and sterol esters in the control of blood cholesterol levels: mechanism and safety aspects. Am J Cardiol 2005, 96:15D-22D.
25. Sarwar R., Neuwirth C., Walji S., et al. Efficacy of ezetimibe and future role of management of refractory hyperlipidaemia in high-risk patients. Br J Cardiol 2008, 15:205-209.
26. Thuluva S.C., Igel M., Giesa U., et al. Ratio of lathosterol to campesterol in serum predicts the cholesterol-lowering effect of sitostanol-supplemented margarine. Int J Clin Pharmacol Ther 2005, 43:305-310.
27. Fransen H.P., de Jong N., Wolfs M., et al. Customary use of plant sterol and plant stanol enriched margarine is associated with changes in serum plant sterol and stanol concentrations in humans. J Nutr 2007, 137:1301-1306.
28. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
29. Lichtenstein A.H., Appel L.J., Brands M., et al. Summary of American Heart Association diet and lifestyle recommendations revision 2006. Arterioscler Thromb Vasc Biol 2006, 26:2186-2191.
30. Arzneimittelkommission der deutschen Ärzteschaft (Drug Commission of the German Medical Profession) Newsletter 2004-2045; 15.01.04.
31. National Institute for Health and Clinical Excellence. LIPID MODIFICATION. Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular diseases, ; [27.12.2009]. http://www.nice.org.uk/nicemedia/pdf/CG67NICEGuideline.pdf.
32. Katan M.B., Grundy S.M., Jones P., et al. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003, 78:965-978.
33. de Jong N., Klungel O.H., Verhagen H., et al. Functional foods: the case for closer evaluation. BMJ 2007, 334:1037-1039.
34. McNamara D.J., Davidson N.O., Samuel P., Ahrens E.H. Cholesterol absorption in man: effect of administration of clofibrate and/or cholestyramine. J Lipid Res 1980, 21:1058-1064.
35. Davidson M.H., Dillon M.A., Gordon B., et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999, 159:1893-1900.
36. Knopp R.H. Drug treatments of lipid disorders. N Engl J Med 1999, 341:498-511.
37. Weingärtner O., Weingärtner N., Scheller B., et al. Alterations in cholesterol homeostasis are associated with coronary heart disease in patients with aortic stenosis. Coron Artery Dis 2009, 20:376-382.
38. Teoh H., Mendelsohn A.A., Goodman S.G., et al. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease. Am J Cardiol 2009, 104:798-804.
39. Farnier M., Averna M., Missault L., et al. Lipid-altering efficacy of ezetimibe/simvastatin 10/20mg compared with rosuvastatin 10mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy-the IN-CROSS study. Int J Clin Pract 2009, 63:547-559.
40. Weingärtner O. Prospective studies testing relevant clinical endpoints are needed. BMJ 2007, Available online: http://www.bmj.com/cgi/elettters/334/7602/1037#171841.
41. Weingärtner O., Böhm M., Laufs U. Plant sterols as dietary supplements for the prevention of cardiovascular diseases. Dtsch Med Wochenschr 2008, 133:1201-1204.